MRVI Earnings Date: Nov 4, 2026 (Estimated) — Maravai LifeSciences Holdings, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is MRVI's next earnings date?
Maravai LifeSciences Holdings, Inc. (MRVI) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.06 on revenue of $43.6M.
How did MRVI do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Maravai LifeSciences Holdings, Inc. posted EPS of -$0.02 versus the -$0.04 estimate, a beat of 60.0%. Revenue was $51.4M against a $48.7M estimate. The stock's 1-day post-earnings move was -0.3%.
How much does MRVI stock move after earnings?
MRVI beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 14.0% (up or down) in the day after earnings.
About Maravai LifeSciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.04 | -0.02 | +60.00% | $51.4M | ✅ Beat | -0.32% | -7.52% | +17.12% |
| 2026-05-07 | Q1 2026 | -0.05 | 0.01 | +120.00% | $65.8M | ✅ Beat | +23.10% | +8.88% | +27.92% |
| 2026-02-25 | Q4 2025 | -0.08 | -0.04 | +50.00% | $49.9M | ✅ Beat | +9.20% | +17.18% | -5.21% |
| 2025-11-06 | Q3 2025 | -0.08 | -0.08 | +0.00% | $41.6M | ➖ Inline | -0.69% | +12.46% | +24.91% |
| 2025-08-11 | Q2 2025 | -0.08 | -0.08 | +0.00% | $47.4M | ➖ Inline | +30.58% | +24.76% | +26.21% |
| 2025-03-18 | Q4 2024 | -0.04 | -0.06 | -50.00% | $56.6M | ❌ Miss | -5.81% | -10.85% | -33.33% |
| 2024-11-07 | Q3 2024 | -0.01 | -0.02 | -100.00% | $65.2M | ❌ Miss | -35.27% | -33.67% | -30.74% |
| 2024-08-07 | Q2 2024 | 0.00 | 0.00 | — | $73.4M | ➖ Inline | -6.87% | -9.67% | -0.55% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q1 FY26 · $65.8M total
| Segment | Share | Revenue | YoY | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 |
|---|---|---|---|---|---|---|---|
| Nucleic Acid Production | 72.1% | $47.5M | +65.1% | $58.5M | $49.9M | $100.4M | $28.8M |
| Biologics Safety Testing | 27.9% | $18.4M | +1.4% | $14.9M | $15.3M | $29.4M | $18.1M |
By region
Q2 FY26 · $51.4M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| North America | 60.8% | $31.3M | +2.1% | $59.0M | $29.3M | $30.6M | $25.0M |
| EMEA | 20.3% | $10.5M | +24.5% | $25.2M | $6.9M | $8.4M | $8.0M |
| Asia Pacific | 18.1% | $9.3M | +14.2% | $45.3M | $10.6M | $8.2M | $8.3M |
| Latin And Central America | 0.8% | $386K | +88.3% | $230K | $146K | $205K | $296K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.